Ari Pollack, MD
Cardiovascular Disease · Fairfield, CTNPI 1427374305
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $4,250 of the $6,815 with a category attached, or 62.4%. Bayer accounts for 62.4% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2021 at $4,250 and has fallen 98.2% since, to $75 in 2023.
Across 15 payments — averaging $454.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$4K
- E.r. Squibb & Sons, L.L.C.$1K
- Abbott$1K
What the payments were for
- Consulting fees$4,25062%
- Speaking & faculty fees$1,25518%
- Travel & lodging$83312%
- Food & beverage$4777%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 1 | $4,250 |
| E.r. Squibb & Sons, L.L.C. | 3 | $1,400 |
| Abbott | 11 | $1,166 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Non-Covered$4,250
- MitraClip$782
How this compares
$6,815 in reported general payments places this provider in the 80th percentile of 415 cardiovascular disease providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 20 | $1,087,363 |
| EliquisApixaban | 667 | $842,230 |
| JardianceEmpagliflozin | 174 | $248,410 |
| EntrestoSacubitril/Valsartan | 124 | $163,717 |
| XareltoRivaroxaban | 118 | $149,905 |
| Repatha SureclickEvolocumab | 81 | $63,116 |
| FarxigaDapagliflozin Propanediol | 57 | $60,761 |
| MultaqDronedarone Hcl | 25 | $57,621 |
| Praluent PenAlirocumab | 72 | $46,957 |
| BrilintaTicagrelor | 38 | $38,195 |
| VascepaIcosapent Ethyl | 46 | $36,248 |
| LivaloPitavastatin Calcium | 29 | $24,672 |
| Rosuvastatin Calcium | 1,411 | $19,509 |
| Repatha PushtronexEvolocumab | 26 | $17,140 |
| Pitavastatin Calcium | 27 | $16,032 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Fairfield
- Nihar DesaiNew Haven$1.4M
- Brett NowlanBloomfield$798K
- Jeffery TestaniNew Haven$546K
- Carlos Mena-HurtadoNew Haven$460K
- Stephanie SaucierHartford$243K
- John ForrestNew Haven$164K
- Henry WardNew Haven$152K
- Ricardo CordidoHamden$135K
- Antonio FernandezHartford$113K
- Paul ThompsonHartford$108K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.